Dr. Richard Fleischhauer

• Global cross-functional project lead: potential of new products in development in inflam./ IBD affected by BioS price (strategic implications for product development) • Development of a D holistic perspective (Medical, Access and Marketing in a team) for various indications to guide product development strategy • Knowledge transfer & discussion with Senior -European Management (Quarterly reviews) • Matrix cooperation with local established brands (insights and customers)

• Head of Marketing (with two direct reports and reporting to BU head), responsible for established products and the successful launch of the first Biosimilar (BioS) monoclonal antibody (mab) in Germany • Hospira circle of excellence award for exceptional performance (Jan 2015) • Exceeding sales goals double times in the first 6 weeks after launch, with ten times higher sales then main competitor (prescribing data after first 6 weeks after launch)

• Establish new benefit based customer relationships and introduce Hospira as an important global pharmaceutical company in the perception of HCPs before and during launch • Development and implementation of the first comprehensive Biosimilar- awareness campaign in Germany • Establishment of new scientific orientated communication concepts to gain access to Drs in a very competitive environment

• Successful repositioning of the third most popular product in the German OTC market (Tebonin®) transforming a double digit loss into an increase in sales of 8% in the first 6 month of 2013 • Launch of the first product to treat Tinnitus in the German market in May 2013 with sales growth absolutely and relatively surpassing forecasts • Developed an umbrella strategy for all products in the field of mental health

• Doubled the sales of ABILIFY® (60 million Euro in 2009 to 130 million Euro in 2012: strongest growth in the market; strongest product & market for BMS Europe) • Developed first comprehensive digital customer-interaction tool for Europe: head of CNS marketing in D and being part of the European innovation team (matrix function). Being responsible in the creation and roll-out of the first comprehensive digital communication campaign (customer e-mail interaction platform, web-cast etc.) for SF

• Awarded brand-responsibility for most important products of Janssen-Cilag, Switzerland (Risperdal and Consta) • Sales growth achievement of more than 20% at the end of the product life-cycle and becoming member of the global strategy team (to help to adopt experience from Switzerland to global positioning strategy) • Successful repositioning of the most important product (Consta) and implementation of the first digital customer interaction tool in the Swiss market

• Represented Germany in the European registration team • Nominated as project leader for the first registration of medical devices • Acted as Pharmacovigilance and Compliance Manager for Germany • Intensive cooperation with marketing department to develop a product registration strategy and marketing materials

• Developed and communicated the internal strategy to the key-account managers • Monitored and communicated success factors to drive sales for the complete Lilly product portfolio within the hospital market • Supported the key-account manager with hospital contract management as well as strategy development

• Sales representative for retail and hospital business • Awarded Sales-Award 2002 for the highest increase in relative market share in Germany • Successful project lead to detect success factors of the best sales reps worldwide to apply for a better sales rep training

Veröffentlichungen in Science/ Journal of Neuroscience/ Speaker beim Congress der Society of Neuroscience in New-Orleans und Miami 1999 und 2000

Forschung in Labor Professor Südhof, Nobel Preis Gewinner 2014

Biophysik

Diplom